Next Wave AntiCancer Therapies Part 1
“In 1890, the Russian playwright and physician Anton Chekov wrote a letter in which he alluded to a centuries-old observation that...
About Me
Jeff leads the Oncology and Virology Practices at Defined Health. Jeff has extensive commercial and strategic perspective on the pharmaceutical and biotech industries. He has directed hundreds of in-depth licensing opportunity and valuation assessments during his tenure at DH. He often speaks at conferences on scientific and commercial issues in cancer, biologics and personalized medicine.
Jeff leads DH's premiere oncology meeting, Cancer Progress. http://www.cancerprogressbydh.com/
Before joining Defined Health, Jeff was a Senior Research Scientist and Research Project Leader in the commercial development of oligonucleotide therapeutics for viral diseases and cancer at Innovir Laboratories; and an Assistant Research Professor at The George Washington University School of Medicine. He has worked closely with two Nobel Prize recipients: Dr. Sidney Altman on ribozymes, and Dr. Stanley Prusiner on prions, and holds four patents in the use of ribozymes.
He received a BA from University of California at San Diego, a PhD in Medical Microbiology from the University of California at Berkeley, and an MA in English/Creative Writing from New York University.
Jeff is a member of the Licensing Executives Society (LES), the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), and the American Society of Gene and Cell Therapy (ASGCT).
Jeff Bockman's Passles
Most Read
Most Shared
Turning Anticancer Therapy Inside-Out (Part I): From Exogenous to Endogenous--Moving Treatment In Situ
Let us begin with the evolution of cancer therapy in a few clauses (and a long Proustian sentence and paragraph): killing the tumor with...
Oncology 2020, the Coming Decade’s Visionary Advances - Part III
In pondering the ongoing discoveries and nascent technologies that could advance the treatment of cancer in the coming decade, I am not...
Oncology 2020, the Coming Decade’s Visionary Advances—Part II
Pondering those cancer circuitry maps such as the one from the updated classic "Hallmarks of Cancer: The Next Generation" by Hanahan and...
The ubiquitous target question for anticancer modalities
Continuing on this theme that Joel has raised in his recent post (“CD19 and BCMA – ‘What if This is as Good as it Gets?’”), I would like...
As a free user, you can follow Passle and like posts.
To repost this post to your own Passle blog, you will need to upgrade your account.
For plans and pricing, please contact our sales team at sales@passle.net